2026
Barry-Simonnet C, Crouzier L, Moujellil-Legagneur T, Chaieb-Errass H, Idres YA, Ferrare K, Rolland M, Cazals G, Poucheret P, Maurice T, Tousch D. Xanthatin-13-(Pyrrolidine-2-Carboxylic Acid), a Sesquiterpene Lactone Isolated From Burdock Leaf, Attenuated Aβ25-35 Toxicity and Memory Deficits in a Pharmacological Mouse Model of Alzheimer’s Disease. Phytother Res. 2026 Mar 7. doi: 10.1002/ptr.70294.
Blanch R, Esandi J, Guerrero-Yagüe R, del Rey J, Roig-Soriano J, Lleo A, Carro E, Mestre-Francés N, Devau G, Ferrer I, Meseguer A, Lanciego JL, Almolda B, Bosch B, Chillón M. sKL/mKL Transcript Ratio and Protein Localization Define a Species- and Region-Specific Klotho Signature in the CNS and AD Progression. Genes and Diseases 2026 (in press)
Coste J, Carcaillon-Bentata L, Robine JM, Trouvin AP, Humphreys J, Guillemin F. Trends in prevalence and disability burden of main rheumatic and musculoskeletal diseases in France 2008-2022. RMD Open. 2026 May 11;12(2):e006584. doi: 10.1136/rmdopen-2025-006584.
Grasso M, Moser PO, Sauvageot S, Gil V, Chan-Seng E, Sanrey E, Coubes P, Poulen G. Putamen Atrophy as a Predictive Factor of Efficacy of GPi-DBS in Dystonia-Dyskinesia Syndrome Secondary to Perinatal Anoxic Encephalopathy. Mov Disord. 2026 Mar 18. doi: 10.1002/mds.70275.
Grasso M, Coelho C, Chan-Seng E, Coubes P, Poulen G. Perinatal Post-Anoxic Spinal Cord Injury: A Barrier to Pallidal Neuromodulation? About 2 Cases. Mov Disord Clin Pract. 2026 Mar 20. doi: 10.1002/mdc3.70602.
Gazard CM, Poulen G, Perrin FE. Glial heterogeneity in the primate spinal cord: Implications of age and sex differences for neurodegenerative and neurotraumatic diseases. Neural Regen Res. 2026 Jan 27. doi: 10.4103/NRR.NRR-D-25-01274.
Hersent C, Larrieu L, Fergelot P, Miro J, Benkirane M, Angelini C, Ramond F, Marelli C, Sabatier I, Lesca G, Vaché C, Cossée M, Bergougnoux A, Dieterich K, Tranchant C, Marey I, Castrioto A, Thauvin-Robinet C, Abou Haidar L, Rivier F, Tuffery-Giraud S, Koenig M. Decoding splicing variants in high-throughput sequencing: a functional validation approach integrating deep learning tools. Eur J Hum Genet. 2026 Aug;34(8):1165-1175. doi: 10.1038/s41431-026-02162-2.
Marelli C, Charret Q, Goizet C, Thevenon J, Bernard V, Ory Magne F, Degoutin M, Fergelot P, Renaud M, Koenig M, Ramond F. STUB1 (SCA48)/TBP (SCA17): A Frequent Association Still Not Fully Explained and a Lower Threshold for Intermediate Expanded TBP Alleles. Mov Disord. 2026 Jul;41(7):1661-1665. doi: 10.1002/mds.70296.
Mastropasqua F, Lisi AT, Crouzier L, Musillo GR, Abatematteo FS, Niso M, Delprat B, Colabufo NA, Nanna V, Mangiatordi GF, Delre P, Spalholz T, Colella M, Deuther-Conrad W, Loiodice F, Maurice T, Laghezza A, Abate C. Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer’s Disease. J Med Chem. 2026 Feb 26;69(4):4613-4628. doi: 10.1021/acs.jmedchem.5c03240.
Maurice T. σ1 receptor agonists: the new trend or an emerging therapeutic option? Expert Opin Emerg Drugs. 2026 Jul 2:1-4. doi: 10.1080/14728214.2026.2696872. .
Menéndez Soto del Valle R, Barry-Simonnet C, Verjus L, Crouzier L, Peña Alcolea S, Sablón Carrazana M, Maurice T, Rodríguez-Tanty C. Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice. J Psychopharmacol. 2026, in press.
Otaegui L, Lehoux J, Begu S, Moujellil-Legagneur T, Zussy C, Vitalis M, Mathias M, Beau A, Durand T, Givalois L, Bernoud-Hubac N, Crauste C, Desrumaux C. Intranasal lipid nanocapsule administration of the new lipophenol quercetin-3-O-DHA-7-O-iPr reduces carbonyl stress and improves behavior in a mouse model of Alzheimer’s disease. Drug Deliv Transl Res. 2026 May 6. doi: 10.1007/s13346-026-02142-5.
Reichau K, Crouzier L, Poeta E, Gehrig T, Schaller E, Zvejniece L, Meunier J, Sotriffer C, Monti B, Maurice T, Decker M. A Dual Approach To Combat Alzheimer’s Disease through Concomitant hBChE Inhibition and S1R Activation. ACS Chem Neurosci. 2026 Feb 18;17(4):805-822. doi: 10.1021/acschemneuro.5c00921.
Reichau K, Crouzier L, Gehrig T, Flake A, Schaller E, Meunier J, Bertrand-Gaday C, Chatonnet A, Zvejniece L, Sotriffer C, Maurice T, Decker M. Targeting neuroinflammation by activation of the sigma-1 receptor (S1R) and inhibition of butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in an Alzheimer’s disease mouse model. Eur J Med Chem. 2026 Mar 5;305:118486. doi: 10.1016/j.ejmech.2025.118486.
Sałaciak K, Lustyk K, Jagielska A, Szafarz M, Inteiro-Oliveira S, Diógenes MJ, Xapelli S, Schnur P, Morton L, Moran E, Ferreira J, Sakata S, Crouzier L, Meunier J, Delprat B, Maurice T, Pytka K. Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction. Neurotherapeutics. 2026 Jan;23(1):e00774. doi: 10.1016/j.neurot.2025.e00774.
Travers-Lesage V, Crouzier L, Antonijevic M, Wang A, Toublet FX, Davis A, Modeste F, Brazzolotto X, Nachon F, Since M, Maurice T, Rochais C, Dallemagne P. Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer’s disease model. Eur J Med Chem. 2026 Apr 5;307:118670. doi: 10.1016/j.ejmech.2026.118670.
Travers–Lesage V, Since M, Wang A, Davis A, Fayolle D, Bernay B, Modeste F, Nachon F, Brazzolotto X, Crouzier L, Sopkova-De Oliveira Santos J, Maurice T, Dallemagne P, Rochais C. Rational design and evaluation of Rivastigmine based pleiotropic prodrugs for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2026 Apr 13. doi: 10.1021/acschemneuro.6c00170